Safety and Efficacy of Probuphine in the Treatment of Opioid Dependence

Inclusion Criteria: * Voluntarily provide written informed consent prior to the conduct of any study related procedures * Male or female, 18-65 years of age * Meet DSM-IV criteria for current opioid dependence * Females of childbearing potential and fertile males must use a reliable means of contraception Exclusion Criteria: * Current diagnosis of Acquired Immune Deficiency Syndrome (AIDS) * Presence of aspartate aminotransferase (AST) levels ≥ 3 X upper limit of normal and/or alanine aminotransferase (ALT) levels ≥ 3 X upper limit of normal and/or total bilirubin ≥ 1.5 X upper limit of normal and/or creatinine ≥ 1.5 X upper limit of normal * Received treatment for opioid dependence (e.g., methadone, BPN), within the previous 90 days * Current diagnosis of chronic pain requiring opioids for treatment * Candidates for only short term opioid treatment or opioid detoxification therapy * Pregnant or lactating females * Previous hypersensitivity or allergy to BPN- or EVA-containing substances or naloxone * Current use of agents metabolized through CYP 3A4 such as azole antifungals (e.g., ketoconazole), macrolide antibiotics (e.g., erythromycin), and protease inhibitors (e.g., ritonavir, indinavir, and saquinavir) * Current anti-coagulant therapy (such as warfarin) or an INR \> 1.2 * Meet DSM-IV criteria for current dependence on any other psychoactive substances other than opioids or nicotine (e.g., alcohol, sedatives) * Current use of benzodiazepines other than physician presc…